WinstonWınston
Back
Agilon Health logo

Agilon Health

AGL
25
Medical - Care Facilities · Healthcare
Price
$96.58
+3.85 (+4.15%)
Market Cap
$1.61B
Exchange
New York Stock Exchange
Winston Score
25
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Weak
Growth
Mixed
Cash Flow
Weak
Stability
Good
Valuation
Data not available

Share count rising — dilution

+11.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 14.9M (2021) → 16.6M (2025)

Winston Score History

The full picture

Agilon Health helps primary care doctors take better care of elderly patients on Medicare. The company partners with physician groups across the United States and takes on the financial responsibility for managing those patients' total healthcare costs. It operates in the Medicare Advantage market, where health insurers pay a fixed amount per patient rather than per service.

Agilon makes money by receiving capitated payments — fixed monthly fees per patient — from Medicare Advantage health plans, then paying for all the medical care those patients need. It operates in multiple U.S. markets and has been growing its network of physician partners. The core idea is that keeping patients healthier costs less, which is how the company aims to eventually turn a profit. However, the company is currently losing money, with medical costs running higher than the payments it receives, and its ability to reach profitability depends heavily on improving how well it manages patient health expenses.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+7.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+117.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

29.8%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~19 months

$251M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

Growth context

Agilon Health is growing revenue at 7% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
7.2%
Thin — 7.2% gross margin
Profit after running costs
Operating Margin
0.8%
Thin — 0.8% operating margin
Return on the money invested
ROCE
-102.8%
Weak — -102.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+0.3%
Nearly flat sales (+0.3% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-1.3%
Burning cash (-1.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.13
Conservative — low debt load (0.13)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial